Detail akcie 4basebio Rg online

Business Summary: 4basebio PLC is a United Kingdom-based life biotechnology company. The Company is focused on the development of advanced therapy medicinal products (ATMPs) through its synthetic Deoxyribonucleic acid (DNA) products and non-viral, cell-targeting nucleic acid delivery platform. The Company offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines. Its synthetic DNA is produced via an enzymatic, cell-free manufacturing process. It utilizes a technology for primer-free DNA amplification called TruePrime, which enables high-yield and quality DNA production. By combining two enzymes, Trueprime technology achieves isothermal multiple displacement DNA amplification in a continuous cell-free process with high fidelity. The Company offers application-specific synthetic DNA solutions across mRNA vaccines and therapies, viral vectors, gene editing, DNA vaccines and non-viral delivery.
Financial Summary: BRIEF: For the six months ended 30 June 2025, 4Basebio PLC revenues increased from L328K to L1.2M. Net loss increased 36% to L7.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Administration expenses increase from L2.2M to L8.9M (expense), Other operating income decrease of 88% to L29K (income), Other operating expenses increase from L6K to L136K (expense).